Modulators of rituximab-induced complement-dependent cytotoxicity in diffuse large B-cell lymphoma
Rituximab, the chimeric monoclonal antibody targeting CD20, forms the cornerstone of therapy for diffuse large B-cell lymphoma (DLBCL). However, more than one-third of patients eventually become unresponsive or resistant to rituximab. Although the mechanisms of action and resistance are not well und...
| Autor principal: | |
|---|---|
| Outros Autores: | |
| Formato: | Final Year Project (FYP) |
| Idioma: | English |
| Publicado em: |
Nanyang Technological University
2021
|
| Assuntos: | |
| Acesso em linha: | https://hdl.handle.net/10356/149717 |